Med Ad News spoke with Nick Bartolomeo and Bryan O’Malley about their new roles at Fingerpaint and the creation of the SHIFT Performance™ Center of Excellence, the capabilities of SHIFT’s AI, the launch of Actionable Intelligence Engine™, and how they think SHIFT will be able to help clients in a proven, science-driven way.
Fingerpaint, a full-service health and wellness marketing agency with five offices across the United States and almost $80 million in revenue, announced the creation of the SHIFT Performance Center of Excellence and the launch of its proprietary Actionable Intelligence Engine.
The healthcare industry is increasingly focusing on niche patient populations. However, finding hard-to-reach rare disease patients is difficult and keeping them engaged over time even more so. Could machine learning platforms that deliver personalized experiences for patients and caregivers be part of the answer?
How machine learning and artificial intelligence can drive clinical innovationAlgorithms, Artificial Intelligence, August 2020, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Data, Health Technology, Innovation, Issue Archives, Machine Learning, Med Ad News, Primary Endpoints, Researchers
Everyone knows the terms “machine learning” and “artificial intelligence.” Few can define them, much less explain their inestimable value to clinical trials. So, it’s not surprising that, despite their ability to minimize risk, improve safety, condense timelines, and save costs, these technology tools are not widely used by the clinical trial industry.
AiCure’s phone app helps clinical trials keep tabs on which participants have taken their medications correctly and which have not.
Frost & Sullivan IDs Five New Technologies to Power Research Across Preclinical Disease Models Published: July 16, 2020 BioSpace When the CEOs of young, innovative biotech companies discuss how their […]
EVERSANA, a leading provider of commercial services to the life science industry, announced the acquisition of HVH Precision Analytics and its predictive analytics platform.
J.P. Morgan Trends: Digital Health Confusion, Tech, Drug Prices and DiversityAcquisitions, Artificial Intelligence, Biomarkers, Biopharma, Biotechnology Innovation Organization (BIO), Business, Data Analysis, Digital Health, Drug Pricing, Financing, Gender diversity, Google, Health Technology, J.P. Morgan Healthcare Conference, Machine Learning, Microsoft, Partnerships
As the J.P. Morgan Healthcare Conference entered the final day for 2020, a few topics rose to the top as trending, including the relative lack of big deals.
Prescription drug errors are a leading source of harm in health care, resulting in substantial morbidity, mortality and health care costs estimated at more than $20 billion annually in the United States.
HVH Precision Analytics announced a proprietary artificial intelligence and machine learning platform used to predict patterns and provide insights to help make informed critical business decisions.